This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Cramer's 'Mad Money' Recap: A New Dawn for Europe?

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.


NEW YORK (TheStreet) -- It's always darkest before the dawn, Jim Cramer said on "Mad Money" Thursday, and the dawn may finally be at hand for Europe. If that's true, he added, then it will be a game-changer for the stock market.

Cramer said he hasn't mentioned Europe of late because up until a few weeks ago there hasn't been anything positive to say. The European markets were continuing to weaken because the central bank opted to raise, rather than lower, interest rates. As the continent's economy ground to a halt, it took China with it because Europe is the largest market for Chinese goods.

But starting two weeks ago, things began to change, Cramer continued. As earnings began rolling in, companies including Eaton (ETN), PPG (PPG), Avnet (AVT) and Timken (TKR) all came on "Mad Money" and said that Europe was finally beginning to bottom.

That trend was confirmed by many of the European banks, which reported better-than-expected numbers, along with General Motors (GM), which indicated sales are beginning to turn positive.

Cramer said with the European Central Bank lowering interest rates just today, it is finally signaling it is interested in making things better rather than worse -- a move that will be a boon for U.S. companies that have been making their European operations leaner and getting ready for the turn that may be at hand now.

If Europe turns positive, it will instantly boost the stocks of U.S. industrials, minerals, oil and gas, banks and technology stocks, said Cramer. It could be the key to higher prices the markets have been waiting for.

Executive Decision: David Pyott

In the "Executive Decision" segment, Cramer spoke with David Pyott, chairman, president and CEO of Allergan (AGN), a company that has seen its shares slide 13% in Wednesday's trading after announcing disappointing data for two of its early-stage drugs.

Pyott started off on a positive note, saying that just today a U.S. Food and Drug Administration committee has recommended approval for its drug Voluma. That positive news is on top of the company's 1-cent-a-share earnings beat on better-than-expected revenue.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,915.07 -70.54 -0.42%
S&P 500 1,964.68 -8.15 -0.41%
NASDAQ 4,396.2040 -22.83 -0.52%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs